ZNTL - Zentalis Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

BiopharmIQ

Try Pro Free Already have an account? Login

Enterprise Value

1.15B

Cash

392.5M

Avg Qtr Burn

-40.71M

Short % of Float

26.10%

Insider Ownership

4.18%

Institutional Own.

-

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ chemo Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-c3 (oral inhibitor of WEE1) Details Uterine disease, Cancer	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Cancer, relapsed or refractory light chain amyloidosis	Phase 1/2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) comb w/ encorafenib and cetuximab Details Cancer, Metastatic colorectal cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Non-Hodgkin lymphoma, Acute myeloid leukemia, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-c5: Oral SERD (Monotherapy) Details Breast cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-c5 (Oral SERD) +Verzenio® (abemaciclib) Details Breast cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.